- ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome
- Topical application of ATR-12 to ex vivo human skin results in superior LEKTI delivery compared to topical LEKTI application
- ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome
- Safe and well tolerated in minipigs
Azitra Reports Preclinical Data Of ATR-12 And Clinical Design On Netherton Syndrome At ASGCT Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.